How a nighttime hormone might affect Alzheimer’s brain changes

Since the previous research note · Earlier expectation not tested

Track continuity

Since the previous research note: Why timing changes the story of melatonin in Alzheimer’s disease

Previous expectation: Earlier melatonin treatment might give people with early cognitive difficulties more time before further decline if longitudinal human research establishes benefit and a tolerable regimen.

What this study adds: The August 11, 2024 review connects multiple proposed biological mechanisms with reports of human cognitive and sleep outcomes and calls for pathology measurements to examine translation. It does not itself test the earlier forecast that treatment changes clinical progression.

---

What changed in this study

Melatonin is best known as the hormone that helps time sleep. Produced mainly at night, it helps signal the biological night to the body and brain. An August 11, 2024 review asks whether that nighttime role could matter for Alzheimer’s disease in ways that extend beyond sleep.

The review brings together findings from cultured cells, animal models, observational research and clinical studies or evidence syntheses. It describes several reasons researchers are interested in melatonin, including possible effects on amyloid-beta, tau, oxidative stress, inflammation and circadian rhythms. But the evidence does not show that melatonin prevents Alzheimer’s disease or slows its clinical progression in people. Better sleep or improved performance on a cognitive test is not the same as protection from Alzheimer’s-related brain damage.

The review asks a bigger question than better sleep

A sleep benefit could still matter to patients, but it answers only part of the Alzheimer’s question. Cognitive tests measure how someone performs at a particular time. Sleep and agitation measures capture symptoms and daily functioning. Alzheimer’s-related pathology refers to biological changes in the brain, including abnormal amyloid-beta and tau. A treatment could influence sleep or test performance without changing those underlying processes.

Melatonin is being considered because it may connect several of these levels. It is a hormone involved in sleep timing and also acts as an antioxidant. In principle, a nighttime signal that improves the conditions around sleep could overlap with pathways involved in cellular injury. The review presents those links as a rationale for research, not as evidence that taking melatonin changes the course of Alzheimer’s disease.

Proposed routes from melatonin to brain injury

Amyloid-beta is a group of protein fragments that can accumulate in the brain as part of Alzheimer’s-related pathology. In cultured neuronal and non-neuronal cells, the review describes melatonin as promoting cleavage of amyloid precursor protein through a route that does not generate amyloid-beta. It also summarizes findings in which melatonin reduced activity associated with the amyloid-producing route. In animal models, those changes were accompanied by lower amyloid-beta levels, although the review also notes that findings were not uniform across doses and models.

The relationship may run in both directions. The review reports that amyloid-beta can reduce melatonin production by the pineal gland. That possibility makes the biology more complicated than a simple one-way treatment effect: disrupted melatonin signaling could be part of a disease-related process, while amyloid-related changes could further disturb the nighttime signal.

Tau is another protein central to Alzheimer’s pathology. When tau becomes excessively phosphorylated, it can contribute to the formation of neurofibrillary tangles and damage inside neurons. The review summarizes rat experiments in which changes in melatonin production were associated with changes in tau phosphorylation, including a reversal after melatonin supplementation in melatonin-deficient animals. It also describes a transgenic mouse model in which melatonin treatment reduced tau hyperphosphorylation, neurofibrillary tangles and neuronal loss. Cell experiments exposed to mercury likewise showed less tau hyperphosphorylation after melatonin pretreatment.

A third route involves oxidative stress, an imbalance between reactive molecules and the body’s antioxidant defenses. In the review’s account, prolonged oxidative stress can activate processes that push amyloid precursor protein toward amyloid-beta production, increase tau phosphorylation, injure neurons and promote neuroinflammation. Melatonin’s antioxidant properties therefore offer a possible way to affect several connected forms of cellular stress. These mechanisms are mainly supported by cell and animal work, not by direct measurements of Alzheimer’s pathology in treated people.

Laboratory mechanisms are not yet human pathology

The human evidence summarized in the review is more indirect. A meta-analysis of 22 randomized controlled trials found that people with Alzheimer’s disease who received melatonin for more than 12 weeks showed improvements on Mini-Mental State Examination scores, particularly among those with mild Alzheimer’s disease. That result is relevant to cognitive function, but a change on a cognitive test does not by itself show that amyloid-beta or tau burden has changed.

The review also describes a cross-sectional study of 1,105 community-dwelling older adults. Higher physiological melatonin levels were correlated with a lower prevalence of depressed mood and cognitive impairment, independently of depressive symptoms. Because this was an observational comparison, it cannot establish that melatonin caused the difference. People with different health, sleep or circadian profiles may also have differed in ways the measurement did not capture.

The authors specifically state that, in their account, published studies had not investigated melatonin’s effect on amyloid-beta burden in humans. They call for studies that measure Alzheimer’s biomarkers in older adults who use melatonin, including brain imaging, cerebrospinal fluid and blood-based measurements. Those measures could test whether a change in cognition or sleep occurs alongside a measurable change in pathology.

Human outcomes span different treatments

The review’s sleep-related evidence also comes from different settings and interventions. It describes a clinical study involving nearly 200 nursing-home residents in the Netherlands. The residents had a mean age of 86, and 87% had dementia. An evening regimen of 2.5 milligrams of melatonin was combined with daytime bright-light exposure for an average of about 15 months. The combined program was associated with less agitated behavior and better sleep.

That finding cannot be assigned to melatonin alone because the intervention included bright light. It also involved a nursing-home population largely affected by dementia, which is not the same as testing a treatment in people with early cognitive difficulties or in people at risk before dementia begins. The review notes that other studies did not find an effect of melatonin on sleep in people with Alzheimer’s disease. Differences in disease stage, treatment response and melatonin-receptor biology may help explain why the findings vary.

The evidence for cognition, sleep and agitation therefore describes several possible benefits in different populations, not one established Alzheimer’s treatment effect. The outcomes are useful because they show what researchers can measure in people. They do not yet demonstrate that melatonin preserves brain tissue or changes clinical progression.

Sleep could be a bridge but still needs measurement

The review proposes one way sleep-related effects might connect to Alzheimer’s biology through the glymphatic system, which is involved in clearing substances from the brain. Melatonin may promote sleepiness and lower the activity of orexin, a wake-promoting neuropeptide. Animal research has linked higher orexin levels during sleep with more amyloid-beta pathology, possibly because of reduced glymphatic function.

The proposed chain remains experimental. In mice exposed to chronic unpredictable stress, melatonin restored a feature of aquaporin-4 organization associated with glymphatic function. That result supports a biological hypothesis in an animal model. It does not show that melatonin increases amyloid-beta or tau clearance in people with Alzheimer’s disease.

Human biomarker studies could examine the missing link. Researchers could compare melatonin exposure with sleep measures and with amyloid-beta or tau measurements from imaging, cerebrospinal fluid or blood. A convincing result would need to connect those measurements to meaningful cognitive or functional outcomes over time. Until then, sleep improvement and pathology modification remain related possibilities rather than interchangeable conclusions.

A plausible treatment needs a reliable regimen

Even if the biology proves useful, the treatment would need more than a promising molecule. Dose, timing, duration and formulation could change what melatonin does. The review discusses differences between immediate-release and extended-release products, as well as the possibility that exposure extending beyond the intended sleeping period could affect whole-body metabolism.

One concern involves glucose regulation. The review describes evidence that chronic melatonin treatment can reduce pancreatic insulin release and raise plasma glucose when exposure continues beyond the sleeping period. It also discusses possible impairment of blood-glucose control when melatonin is taken with carbohydrate-rich meals. These are treatment-design concerns, not proof that every user will experience the same effect.

The review also raises practical safety questions for older adults. Dose-related drowsiness could increase the risk of nighttime falls, and the authors discuss possible worsening of breathing difficulties in people with obstructive sleep apnea. Supplement consistency presents another problem: labeled amounts may not match actual contents, and pharmacokinetics can vary between products. A naturally occurring hormone is not automatically a self-adjusting or risk-free treatment.

Those details matter because a future Alzheimer’s regimen would likely need to be used repeatedly over a long period. The relevant question is not simply whether melatonin can influence a pathway in a cell or improve sleep under one set of conditions. It is whether a reproducible dose and timing can produce meaningful benefits while remaining tolerable for the people most likely to use it.

What an accessible treatment could mean for Alzheimer’s care

The review identifies melatonin’s affordability and accessibility as reasons for further testing. If a tolerable regimen were shown to preserve cognitive function, it could help patients retain abilities they use in daily life and ease some demands on families and professional caregivers. Whether a tested Alzheimer’s regimen would retain those cost and access advantages would also need to be established.

That future remains conditional from the August 2024 perspective. It depends on human research establishing meaningful effects on progression, linking those effects to measurable brain pathology, and identifying a dose, timing and formulation suitable for sustained use. Only then could patients gain an affordable, accessible option for preserving cognitive function, with benefits extending to the people who support their care.

Key Sources

• Primary source: Melatonin: A potential nighttime guardian against Alzheimer's.
  DOI or Journal Page · Review or Meta-Analysis · 2024-08-11